Good morning :)
Place Order
Add to Watchlist

Kimia Biosciences Ltd

KIMIABL

Kimia Biosciences Ltd

KIMIABL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹229 cr, stock is ranked 2,397
High RiskStock is 3.98x as volatile as Nifty
48.282.86% (-1.42)
48.282.86% (-1.42)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹229 cr, stock is ranked 2,397
High RiskStock is 3.98x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹229 cr, stock is ranked 2,397
High RiskStock is 3.98x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
79.7442.06
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company makes bulk drug intermediates. It manufactures bulk drugs intermediates for Indian pharmaceutical companies on contract manufacturing basis. It also offers finish goods and fine chemicals.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 2.26%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.04% to 0.03%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.382.0577.3295.25107.25135.17125.83129.73106.52108.35
Raw Materialssubtract0.080.3560.5872.2279.09103.1396.03106.39105.3696.83
Power & Fuel Costsubtract0.310.171.852.543.214.546.547.29
Employee Costsubtract2.130.837.808.8210.8014.0915.0816.40
Selling & Administrative Expensessubtract0.400.612.322.333.764.886.167.04
Operating & Other expensessubtract0.650.481.442.434.97-2.300.46-2.58
Depreciation/Amortizationsubtract0.290.351.141.101.661.912.943.333.293.33
Interest & Other Itemssubtract0.560.270.582.002.533.393.644.255.054.80
Taxes & Other Itemssubtract0.01-0.08-0.06-0.05-0.160.43-1.32-3.04-1.880.51
EPS-5.48-1.261.522.640.461.09-0.78-1.98-1.120.61
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kimia Biosciences Ltd-43.3342.06
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare KIMIABL with any stock or ETF
Compare KIMIABL with any stock or ETF
KIMIABL
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.94%0.38%0.00%0.00%24.68%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

KIMIABL has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Kimia Biosciences to convene AGM

Kimia Biosciences announced that the Annual General Meeting(AGM) of the company will be held on 28 December 2024.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Kimia Biosciences to conduct board meeting

Kimia Biosciences will hold a meeting of the Board of Directors of the Company on 5 December 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Kimia Biosciences reports standalone net profit of Rs 1.61 crore in the September 2024 quarter

Net profit of Kimia Biosciences reported to Rs 1.61 crore in the quarter ended September 2024 as against net loss of Rs 2.44 crore during the previous quarter ended September 2023. Sales rose 16.45% to Rs 28.18 crore in the quarter ended September 2024 as against Rs 24.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales28.1824.20 16 OPM %11.96-8.10 - PBDT2.70-2.44 LP PBT1.91-3.26 LP NP1.61-2.44 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Kimia Biosciences to discuss results

Kimia Biosciences will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Kimia Biosciences reports standalone net profit of Rs 1.44 crore in the June 2024 quarter

Net profit of Kimia Biosciences reported to Rs 1.44 crore in the quarter ended June 2024 as against net loss of Rs 2.71 crore during the previous quarter ended June 2023. Sales declined 7.55% to Rs 22.40 crore in the quarter ended June 2024 as against Rs 24.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales22.4024.23 -8 OPM %16.61-6.77 - PBDT2.69-2.79 LP PBT1.79-3.62 LP NP1.44-2.71 LP Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Kimia Biosciences announces board meeting date

Kimia Biosciences will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Kimia Biosciences gets recognition for supply of pharmaceutical raw material to Bangladesh

2 years agoIndia Infoline

Kimia Biosciences hits the roof after validation in Bangladesh

2 years agoBusiness Standard

Stocks that will see action today

2 years agoThe Hindu Businessline

Kimia Biosciences reports standalone net loss of Rs 1.27 crore in the September 2021 quarter

3 years agoBusiness Standard